Bioequivalence study of dihydroartemisinin-piperaquine (DHP) generic formulation in fixed-dose combination, in healthy Indonesian volunteers

Ani Isnawati, Retno Gitawati, Mariana Raini, Indri Rooslamiati, Lanny Marliany, Effi Setiawati, Vivi Setiawaty

Ani Isnawati

Retno Gitawati

Mariana Raini

Indri Rooslamiati

Lanny Marliany
Indofarma, Jakarta

Effi Setiawati
Equilab International, Jakarta

Vivi Setiawaty
National Institute of Health Research and Development / Badan Litbang Kesehatan. Email: vivisetiawaty@hotmail.com
Online First: August 05, 2018 | Cite this Article
Isnawati, A., Gitawati, R., Raini, M., Rooslamiati, I., Marliany, L., Setiawati, E., Setiawaty, V. 2018. Bioequivalence study of dihydroartemisinin-piperaquine (DHP) generic formulation in fixed-dose combination, in healthy Indonesian volunteers. Bali Medical Journal 7(2): 290-295. DOI:10.15562/bmj.v7i2.822

Background: Malaria is still considered as a major health problem in the world including in Indonesia, which is regarded as one of the malaria-endemic countries. Since 2006, WHO has recommended the use of artemisinin-based combination therapy (ACT) to treat uncomplicated falciparum malaria. In Indonesia, DHP tablet (combination of dihydroartemisinin and piperaquine) is the first line therapy used in malaria control program, which currently used imported DHP tablet. To produce generic DHP tablet, comparative bioequivalence test between DHP tablet and the drug previously used is needed. Methods: A single dosed, randomized, double-blinded, one-period, and parallel study design was conducted in the present research. Every twenty-four subjects were assigned into two groups, which are test group and comparison group. Results: The results showed that even though in vitro comparison of dissolution test has fulfilled the requirements, in vivo test results has not fulfilled the bioequivalence standards. Obtained geometric mean ratios (90% confidence intervals) of the test drug to comparator drug for dihydroartemisinin were 83.30% (67.06%–103.48%) for AUC0-t, 83.24% (67.10%–103.26%) for AUC0-inf, and 75.67% (61.83%–92.61%) for Cmax. The geometric mean ratios (90% confidence intervals) of the test drug to comparator drug for piperaquine were 97.31% (76.50%–123.80%) for AUC0-t, 94.18% (74.18%–119.59%) for AUC0-inf, and 96.47% (71.80%–129.62%) for Cmax. Conclusions: Therefore, the pharmacokinetic profile of the test drug is concluded to be bio-inequivalent with the comparator drug.


Cui L, Su XZ. Discovery, Mechanisms of Action and Combination Therapy of Artemisinin, Published in final edited form as: Expert Rev Anti Infect Ther. 2009;7(8):999-1013. doi: 10.1586/eri.09.68. Review. PMID: 19803708, NIH Public Access

World Health Organization. Guidelines for the Treatment of Malaria. WHO; Geneva: 2006

Kementerian kesehatan RI, Peraturan Menteri Kesehatan Republik Indonesia Nomor 5 Tahun 2013 tentang Pedoman Tata Laksana Malaria, Jakarta, 7 January 2013

Brown G. Artemisinin and New Generation of antimalarial drugs, Education in Chemistry. 2006. Available in https://eic.rsc.org/section/feature/artemisinin-and-a-new-generation-of-antimalarial-drugs/2020095.article

The Chinese Pharmacopoeia, volume II, 2010

Committee for medicinal products for human, (CHMP) Guideline on the investigation of bioequivalence, European Medicines Agency (EMEA), Doc. Ref.: CPMP/EWP/QWP/1401/98 Rev. 1/ Corr **, London, 20 January 2010

Peraturan kepala badan pengawas obat dan Makanan, Nomor : HK. tentang pedoman uji bioekivalensi, Jakarta, 29 Maret, 2005

Badan Pengawas Obat dan Makanan. Pedoman Metodologi Uji Bioekivalensi Spesifik Zat Aktif. Jakarta: Badan POM; 2011.

Patrick JM. History and Evolution of the Dissolution Test. Dissolution Technologies. 2014:11-16. dx.doi.org/10.14227/DT210314P11

Chinh NT, Quang NN, Thanh NX, Dai B, Geue JP, Addison RS, et al. Pharmacokinetics and Bioequivalence Evaluation of Two Fixed-Dose Tablet Formulations of Dihydroartemisinin and Piperaqune in Vietnamese Subjects. Antimicrobial Agent and Chemotheraphy. 2009; 53(2): 828-831. doi:10.1128/AAC.00927-08.

Kubbinga M, Langguth P, Barends D. Risk Analysis in Bioequivalence and Bio waiver Decisions, Biopharmaceutics & Drug Disposition. 2013; 34(5): 254-261, doi: 10.1002/bdd.1831.

Patel JN, Rathod DM, Patel NA, Modasiya MK. Techniques to Improve the Solubility of Poorly Soluble Drugs, International Journal of Pharmacy & Life Sciences, Int. J. Of Pharm. & Life Sci. (IJPLS). 2012; 3(2): 1459-1469.

A Comparative Analysis of Biopharmaceutics Classification System and Biopharmaceutics Drug Disposition Classification System : a Cross-Sectional Survey with 500 bioequivalence Studies. Journal of Pharmaceutical Sciences. 2013; 102(9):3136-3144. doi: 10.1002/jps

No Supplementary Material available for this article.
Article Views      : 0
PDF Downloads : 0